Physician profile
Anand Singla
NPI 1639207707
$5,999.38
in general payments reported to CMS, 2019-2025
29 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $391 · 2021: $1,226 · 2022: $929 · 2023: $616 · 2024: $808 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $859.29 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $747.03 | 2020-2025 | Nexletol |
| Pfizer INC. | $696.89 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $481.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $405.99 | 2019-2024 | Xarelto |
| Amgen INC. | $296.35 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $293.84 | 2020-2025 | Lifevest |
| Boston Scientific Corporation | $253.11 | 2022-2025 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $247.48 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $234.23 | 2019-2024 | Farxiga |
| Shockwave Medical, INC | $209.56 | 2025 | |
| Edwards Lifesciences Corporation | $165.42 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $156.32 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Scpharmaceuticals INC. | $120.23 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.41 | 2021-2023 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $110.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.49 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $83.11 | 2023-2024 | Inpefa |
| Glaxosmithkline, LLC. | $76.84 | 2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $75.83 | 2025 | Inspire |
| Astellas Pharma US INC | $60.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $51.60 | 2019-2024 | |
| Medtronic Vascular, INC. | $51.29 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $23.26 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $18.67 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.49 | 2022 | |
| Chiesi USA, INC. | $17.06 | 2025 | Juxtapid |
| Amarin Pharma, INC. | $16.88 | 2020 | |
| Philips North America LLC | $16.88 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.